Release Date: 03/12/21 14:38 Summary: Change of Director's Interest, Appendix 3Y - Tim Goldsmith Price Sensitive: No Download Document 176.24KB Download
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress